Natera, Inc. (NTRA)

業務介紹

Natera, Inc.是一家診斷公司，全球開發和商業化分子檢測服務。該公司提供Panorama，一種非侵入性產前檢測，通過從母親的血液中提取檢測，篩查胎兒的染色體異常，以及雙胞胎懷孕的同卵性；Vistara，一種單基因突變篩查檢測，用於確定單基因疾病；Horizon遺傳帶菌者篩查，用於確定各種遺傳疾病的帶菌狀態；以及Spectrum，用於在體外受精周期中檢測染色體異常或遺傳疾病。該公司還提供Anora流產檢測產品，分析胎兒染色體以了解流產原因；以及非侵入性親子鑑定檢測產品，通過從懷孕母親和聲稱的父親提取血液進行鑑定。此外，該公司還提供Constellation，一種基於雲端的軟件產品，使實驗室客戶能夠通過雲端獲取該公司的算法和生物信息學，以驗證和推出檢測；Signatera，一種循環腫瘤DNA技術，獨立於個體腫瘤篩查一組通用突變；以及Prospera，用於評估器官移植排斥。該公司通過直接銷售團隊以及約100家實驗室和分銷合作夥伴提供產品。該公司與BGI Genomics Co., Ltd.達成合作協議，開發、製造和商業化基於NGS的基因檢測試劑；與Foundation Medicine, Inc.達成合作協議，開發和商業化個性化循環腫瘤DNA監測試劑。該公司前身為Gene Security Network, Inc.，於2012年改名為Natera, Inc.，成立於2003年，總部位於德克薩斯州奧斯汀。

Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. It offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother, as well as twin pregnancies for zygosity; Vistara, a single-gene mutations screening test to identify single-gene disorder; Horizon carrier screening to determine carrier status for various genetic diseases; and Spectrum to identify chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle. The company also provides Anora miscarriage test products to analyze fetal chromosomes to understand the cause of miscarriage; and non-invasive paternity testing products to determine paternity by gestation using a blood draw from the pregnant mother and alleged father. In addition, it offers Constellation, a cloud-based software product that enables laboratory customers to gain access through the cloud to the company's algorithms and bioinformatics in order to validate and launch tests; Signatera, a circulating tumor DNA technology that screen for a generic set of mutations independent of an individual's tumor; and Prospera used to assess organ transplant rejection. The company offers products through its direct sales force, as well as through a network of approximately 100 laboratory and distribution partners. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays; and Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. The company was formerly known as Gene Security Network, Inc. and changed its name to Natera, Inc. in 2012. Natera, Inc. was founded in 2003 and is based in Austin, Texas.

公司網址

https://www.natera.com